Biocryst Pharmaceuticals (BCRX) Depreciation & Amortization (CF) (2010 - 2026)
Biocryst Pharmaceuticals' (BCRX) quarterly Depreciation & Amortization (CF) came in at $461000.0 in Q1 2026, up 39.27% YoY from $331000.0 in Q1 2025, and up 17.01% on a QoQ basis from $394000.0 in Q4 2025.
Biocryst Pharmaceuticals (BCRX) Depreciation & Amortization (CF) (2010 - 2026) Analysis & Trends
Biocryst Pharmaceuticals (BCRX) has 17 years of Depreciation & Amortization (CF) data on file, last reported at $461000.0 in Q1 2026.
- Quarterly Depreciation & Amortization (CF) rose 39.27% year-over-year to $461000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.5 million (up 19.51% YoY) and the FY2025 annual result came in at $1.4 million, up 11.48% from the prior year.
- Depreciation & Amortization (CF) improved to $461000.0 in Q1 2026, from $394000.0 in the prior quarter.
- In the past five years, Depreciation & Amortization (CF) ranged from a high of $461000.0 in Q1 2026 to a low of $306000.0 in Q1 2024.
- A 5-year average of $364000.0 and a median of $335000.0 in 2022 frame the typical range for Depreciation & Amortization (CF).
- Annual changes were most pronounced in 2022 — Depreciation & Amortization (CF) surged 131.58% — and 2024, when it decreased 26.95%.
- Tracing BCRX's Depreciation & Amortization (CF) over 5 years: stood at $396000.0 in 2022, then grew by 6.82% to $423000.0 in 2023, then decreased by 26.95% to $309000.0 in 2024, then advanced by 27.51% to $394000.0 in 2025, then grew by 17.01% to $461000.0 in 2026.
- The last three Depreciation & Amortization (CF) figures came in at $461000.0 (Q1 2026), $394000.0 (Q4 2025), and $335000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.91 Bn | 42.95 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.15 Bn | 39.49 Bn | 2.15 Bn | 241.00 Mn |
| 3 | Zoetis | 31.52 Bn | 29.84 Bn | 1.05 Bn | 119.00 Mn |
| 4 | Takeda Pharmaceutical | 28.58 Bn | 22.78 Bn | 5.10 Bn | 1.02 Bn |
| 5 | United Therapeutics | 22.16 Bn | 19.50 Bn | 683.80 Mn | 24.20 Mn |
| 6 | Viatris | 18.76 Bn | 17.87 Bn | 1.46 Bn | 672.30 Mn |
| 7 | Neurocrine Biosciences | 15.48 Bn | 15.09 Bn | 935.80 Mn | - |
| 8 | Elanco Animal Health | 11.69 Bn | 11.16 Bn | 798.00 Mn | 171.00 Mn |
| 9 | Dr Reddys Laboratories | 10.13 Bn | 9.96 Bn | - | - |
| 10 | Biocryst Pharmaceuticals | 2.46 Bn | 2.11 Bn | 214.41 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 513,000.00 |
| Jun 30, 2026 | 513,000.00 |
| Mar 31, 2026 | 461,000.00 |
| Mar 31, 2026 | 461,000.00 |
| Dec 31, 2025 | 394,000.00 |
| Dec 31, 2025 | 394,000.00 |
| Sep 30, 2025 | 335,000.00 |
| Sep 30, 2025 | 335,000.00 |
| Jun 30, 2025 | 329,000.00 |
| Jun 30, 2025 | 329,000.00 |
| Mar 31, 2025 | 331,000.00 |
| Mar 31, 2025 | 331,000.00 |
| Dec 31, 2024 | 309,000.00 |
| Dec 31, 2024 | 309,000.00 |
| Sep 30, 2024 | 311,000.00 |
| Sep 30, 2024 | 311,000.00 |
| Jun 30, 2024 | 320,000.00 |
| Jun 30, 2024 | 320,000.00 |
| Mar 31, 2024 | 306,000.00 |
| Mar 31, 2024 | 306,000.00 |